XENE -22% on failed phase-2b in osteoarthritis: http://finance.yahoo.com/news/teva-xenon-tv-45070-phase-120000023.html Results from this trial showed that TV-45070 4% and 8% did not demonstrate statistically significant difference from placebo in efficacy endpoints of reductions in pain due to OA. Teva is XENE’s partner on this program. There was a CC earlier this morning.